Literature DB >> 25421280

Radiotherapy. Gazing at the crystal ball of European radiotherapy.

Jens Overgaard1.   

Abstract

Although radiotherapy is a key component of cancer treatment, provision of this modality is not immune to limits placed on health-care expenditure. Recent studies suggest European radiation oncology resources will generally be insufficient to meet future, and in some cases current, needs. This challenge and how it might be addressed is discussed herein.

Entities:  

Mesh：

Year:  2014        PMID： 25421280     DOI： 10.1038/nrclinonc.2014.205

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Radiation therapy infrastructure and human resources in low- and middle-income countries: present status and projections for 2020.

Authors:  Niloy R Datta; Massoud Samiei; Stephan Bodis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-18       Impact factor: 7.038

2.  Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey.

Authors:  Cai Grau; Noémie Defourny; Julian Malicki; Peter Dunscombe; Josep M Borras; Mary Coffey; Ben Slotman; Marta Bogusz; Chiara Gasparotto; Yolande Lievens; Arianit Kokobobo; Felix Sedlmayer; Elena Slobina; Karen Feyen; Tatiana Hadjieva; Karel Odrazka; Jesper Grau Eriksen; Jana Jaal; Ritva Bly; Bruno Chauvet; Normann Willich; Csaba Polgar; Jakob Johannsson; Moya Cunningham; Stefano Magrini; Vydmantas Atkocius; Michel Untereiner; Martin Pirotta; Vanja Karadjinovic; Sverre Levernes; Krystol Sladowski; Maria Lurdes Trigo; Barbara Šegedin; Aurora Rodriguez; Magnus Lagerlund; Bert Pastoors; Peter Hoskin; Jaap Vaarkamp; Ramon Cleries Soler
Journal:  Radiother Oncol       Date:  2014-10-31       Impact factor: 6.280

3.  Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database.

Authors:  Eduardo Rosenblatt; Joanna Izewska; Yavuz Anacak; Yaroslav Pynda; Pierre Scalliet; Mathieu Boniol; Philippe Autier
Journal:  Lancet Oncol       Date:  2013-01-24       Impact factor: 41.316

4.  Radiotherapy capacity in Europe.

Authors:  Cai Grau; Josep M Borras; Julian Malicki; Ben Slotman; Peter Dunscombe; Mary Coffey; Donal Hollywood; Ferran Guedea; Chiara Gasparotto; Yolande Lievens
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

5.  Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey.

Authors:  Peter Dunscombe; Cai Grau; Noémie Defourny; Julian Malicki; Josep M Borras; Mary Coffey; Marta Bogusz; Chiara Gasparotto; Ben Slotman; Yolande Lievens; Arianit Kokobobo; Felix Sedlmayer; Elena Slobina; Olivier De Hertogh; Tatiana Hadjieva; Jiri Petera; Jesper Grau Eriksen; Jana Jaal; Ritva Bly; David Azria; Michael Baumann; Zoltan Takacsi-Nagy; Jakob Johannson; Moya Cunningham; Stefano Magrini; Vydmantas Atkocius; Michel Untereiner; Martin Pirotta; Vanja Karadjinovic; Sverre Levernes; Marian Reinfuss; Maria Lurdes Trigo; Valentin Cernea; Pavol Dubinsky; Barbara Šegedin; Jose Lopez Torrecilla; Bert Pastoors; Roger Taylor; Scott Taylor
Journal:  Radiother Oncol       Date:  2014-09-19       Impact factor: 6.280

6.  Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey.

Authors:  Yolande Lievens; Noémie Defourny; Mary Coffey; Josep M Borras; Peter Dunscombe; Ben Slotman; Julian Malicki; Marta Bogusz; Chiara Gasparotto; Cai Grau; Arianit Kokobobo; Felix Sedlmayer; Elena Slobina; Philippe Coucke; Roumen Gabrovski; Milan Vosmik; Jesper Grau Eriksen; Jana Jaal; Catherine Dejean; Csaba Polgar; Jakob Johannsson; Moya Cunningham; Vydmantas Atkocius; Carlo Back; Martin Pirotta; Vanja Karadjinovic; Sverre Levernes; Boguslaw Maciejewski; Maria Lurdes Trigo; Barbara Šegedin; Amalia Palacios; Bert Pastoors; Charlotte Beardmore; Sara Erridge; Gaile Smyth; Ramon Cleries Soler
Journal:  Radiother Oncol       Date:  2014-11-12       Impact factor: 6.280

7.  Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project.

Authors:  Søren M Bentzen; Germaine Heeren; Brian Cottier; Ben Slotman; Bengt Glimelius; Yolande Lievens; Walter van den Bogaert
Journal:  Radiother Oncol       Date:  2005-03-16       Impact factor: 6.280

8.  Radiotherapy infrastructure and human resources in Europe - present status and its implications for 2020.

Authors:  Niloy Ranjan Datta; Massoud Samiei; Stephan Bodis
Journal:  Eur J Cancer       Date:  2014-07-29       Impact factor: 9.162

Review 9.  Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012.

Authors:  Michael B Barton; Susannah Jacob; Jesmin Shafiq; Karen Wong; Stephen R Thompson; Timothy P Hanna; Geoff P Delaney
Journal:  Radiother Oncol       Date:  2014-05-12       Impact factor: 6.280
  9 in total
  5 in total

1.  [Kyphoplasty combined with intraoperative radiotherapy (Kypho-IORT). Alternative therapy for patients with oligometastatic spinal metastases].

Authors:  F Bludau; T Reis; F Schneider; S Clausen; F Wenz; U Obertacke
Journal:  Radiologe       Date:  2015-10       Impact factor: 0.635

Review 2.  Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment.

Authors:  J E Scaife; G C Barnett; D J Noble; R Jena; S J Thomas; C M L West; N G Burnet
Journal:  Br J Radiol       Date:  2015-05-26       Impact factor: 3.039

3.  Biomedical Research Goes Viral: Dangers and Opportunities.

Authors:  Eleftheria Zeggini; Michael Baumann; Magdalena Götz; Stephan Herzig; Martin Hrabe de Angelis; Matthias H Tschöp
Journal:  Cell       Date:  2020-05-11       Impact factor: 41.582

Review 4.  What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond.

Authors:  Michael Baumann; Nadja Ebert; Ina Kurth; Carol Bacchus; Jens Overgaard
Journal:  Mol Oncol       Date:  2020-06-30       Impact factor: 6.603

Review 5.  Provision and use of radiotherapy in Europe.

Authors:  Yolande Lievens; Josep M Borras; Cai Grau
Journal:  Mol Oncol       Date:  2020-05-01       Impact factor: 6.603
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.